March 3, 2026Open Access

Efficacy for LDL-C–lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

Key Points

Pemafibrate effectively reduces LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels.
The significant reduction in LDL-C highlights pemafibrate as a viable treatment alternative for this patient group.

Structured PICO

Does pemafibrate extended-release formulation reduce LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels?

Population

Patients with statin-intolerant hypercholesterolemia and normal triglyceride levels

Intervention

Pemafibrate extended-release formulation

Comparator

Placebo

Outcome

LDL-C loweringsurrogate

Pemafibrate extended-release formulation effectively reduces LDL-C in statin-intolerant patients with normal triglycerides, offering a potential new therapeutic option.

Abstract

Pemafibrate effectively and safely reduces LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels, offering a potential new therapeutic option for this population.

Bookmark

View Full Paper

Cite This Study

Yamashita et al. (Thu,) studied this question.

synapsesocial.com/papers/69a759e1c6e9836116a1f435 https://doi.org/https://doi.org/10.1016/j.jacl.2026.01.008

Bookmark

View Full Paper